$TYRA News
Last published 2d ago
- 2d agoTYRATyra Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoTYRATyra Biosciences Reports Third Quarter 2026 Financial Results and Recent HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
- 1mo agoTYRATyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2mo agoTYRADabogratinib: the first oral innovation in IR NMIBC - TYRA BIOSCIENCES INCEarnings Call TranscriptsWelcome to Tyra Biosciences' webcast and conference call on the initial SRF302 results. Today's conference is being recorded. At this time, I would like to turn the call over to Todd Harris. Please go ahead. Thank you, O
- 2mo agoTYRATyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with DabogratinibPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2mo agoTYRATyra Biosciences to Present at the Cantor Global Healthcare ConferencePR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2mo agoTYRATyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 3mo agoTYRATyra Biosciences Reports Second Quarter 2026 Financial Results and Recent HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 5mo agoTYRAJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - TYRA BIOSCIENCES INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Todd Harris, the CEO of Tyra. It's an exciting time for the company. Todd's going to give an intro with a cou
- 5mo agoTYRATYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAYPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 6mo agoTYRATyra Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 6mo agoTYRATyra Biosciences to Participate in Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 6mo agoTYRATyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 8mo agoTYRATyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 8mo agoTYRATyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers SymposiumPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 8mo agoTYRATyra Biosciences to Participate in Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 11mo agoTYRATyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory OfficerPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Participation at Upcoming Investor EventsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Reports Third Quarter 2025 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Participation at Upcoming Investor EventsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Reports Second Quarter 2025 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call SeriesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences to Participate at Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences to Present at Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Appointment of Adele Gulfo to Board of DirectorsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 1y agoTYRATyra Biosciences to Present at Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences to Present at the 2024 Cantor Global Healthcare ConferencePR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Appoints Doug Warner, M.D., as Chief Medical OfficerPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Reports Second Quarter 2024 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)PR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences to Present at Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Reports First Quarter 2024 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of DirectorsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and HighlightsPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences to Present at Upcoming Investor ConferencesPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences ConferencePR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences, Inc. Announces $200 Million Private Placement FinancingPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
- 2y agoTYRATyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of AchondroplasiaPR NewswireTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...